Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Oct 05, 2020 9:00am EDT

CohBar to Present at the BIO Investor Forum

Sep 29, 2020 4:05pm EDT

CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

Sep 10, 2020 4:05pm EDT

CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit

Sep 03, 2020 8:45am EDT

CohBar to Present at the H.C. Wainwright Annual Global Investment Conference

Aug 28, 2020 4:05pm EDT

CohBar Announces Closing of Public Offering of Common Stock and Warrants

Aug 26, 2020 8:30am EDT

CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants

Aug 25, 2020 4:55pm EDT

CohBar Announces Proposed Public Offering of Common Stock and Warrants

Aug 24, 2020 9:00am EDT

CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Aug 13, 2020 4:03pm EDT

CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update

Aug 05, 2020 9:00am EDT

CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference